Tech Company Financing Transactions
Tessera Therapeutics Funding Round
Tessera Therapeutics closed a venture capital round on 12/18/2024. Backers included Bill & Melinda Gates Foundation.
Transaction Overview
Company Name
Announced On
12/18/2024
Transaction Type
Venture Equity
Amount
Unknown
Round
Undisclosed
Investors
Proceeds Purpose
The company intends to use the funds to advance a SCD treatment and further its objectives to develop genetic medicines that are accessible globally.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
55 Cambridge Pkwy. 800E
Cambridge, MA 02142
USA
Cambridge, MA 02142
USA
Phone
Undisclosed
Website
Email Address
Overview
Tessera Therapeutics is an early-stage life sciences company pioneering Gene Writing, a new biotechnology designed to offer scientists and clinicians the ability to write small and large therapeutic messages into the genome, thereby curing diseases at their source.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Geoffrey von Maltzahn
Chief Scientific Officer
Jacob Rubens
Vice President
Stephen Cleaver
Vice President
Cecilia Cotta-Ramusino
VP - Bus. Development
Vikram Ranade
Browse more venture capital transactions:
Prev: 12/18/2024: BVNK venture capital transaction
Next: 12/18/2024: Bureau venture capital transaction
Share this article
About Database of VC Transactions
We do our best to document every notable VC transaction. All VC database entries on this site come from publicly available VC deal announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs